A Phase 2 HAE Prophylaxis Study With Recombinant Human C1 Inhibitor
Public ClinicalTrials.gov record NCT02247739. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, 3-Period Crossover Study to Evaluate the Efficacy and Safety of Recombinant Human C1 Inhibitor in the Prophylaxis of Angioedema Attacks in Patients With Hereditary Angioedema (HAE)
Study identification
- NCT ID
- NCT02247739
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Pharming Technologies B.V.
- Industry
- Enrollment
- 32 participants
Conditions and interventions
Conditions
Interventions
- Recombinant human C1 inhibitor Biological
- Placebo Other
Biological · Other
Eligibility (public fields only)
- Age range
- 13 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2014
- Primary completion
- Apr 30, 2016
- Completion
- Aug 31, 2016
- Last update posted
- Dec 7, 2017
2014 – 2016
United States locations
- U.S. sites
- 4
- U.S. states
- 3
- U.S. cities
- 3
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of South Florida Asthma, Allergy and Immunology Clinical Research Unit | Tampa | Florida | 33613 | — |
| University of South Florida, Asthma, Allergy & Immunology Clinical Research Unit | Tampa | Florida | 33613 | — |
| Washington University Division of Allergy and Immunology | St Louis | Missouri | 63141 | — |
| Baker Allergy, Asthma and Dermatology Research Center | Lake Oswego | Oregon | 97035 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02247739, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 7, 2017 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02247739 live on ClinicalTrials.gov.